Allos Therapeutics seeks funds for anticancer candidate
This article was originally published in Scrip
Executive Summary
Allos Therapeutics plans to raise as much as $150 million in a common offering of up to 26.1 million shares. The firm will use the proceeds to advance its only clinical candidate, the anticancer agent pralatrexate, towards a potential commercial launch and for general corporate purposes.